Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHR | P35869 | 7/20 | 0.62 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.58 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | IKBKB | O14920 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | KMO | O15229 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29351484 | 1.00 | AHR (0.62) | AHRCYP1B1MEN1HTTKMT2A | |
| SCHEMBL29776918 | 1.00 | AHR (0.62) | AHRCYP1B1MEN1HTTKMT2A | |
| SCHEMBL4450479 | 0.85 | AHR (0.65) | AHRCYP1B1MEN1HTTKMT2A | |
| SCHEMBL23827192 | 0.82 | AHR (0.65) | AHRCYP1B1MEN1HTTKMT2A | |
| SCHEMBL30226161 | 0.82 | AHR (0.56) | AHRCYP1B1CYP3A4TSHRHSD17B10 | |
| SCHEMBL4449577 | 0.82 | AHR (0.56) | AHRCYP1B1CYP3A4TSHRHSD17B10 | |
| SCHEMBL4449757 | 0.81 | AHR (0.60) | AHRCYP1B1MEN1HTTKMT2A | |
| SCHEMBL4456561 | 0.80 | AHR (0.62) | AHRCYP1B1MEN1HTTKMT2A | |
| SCHEMBL11613007 | 0.79 | AHR (0.48) | AHRCYP1B1MEN1HTTKMT2A | |
| SCHEMBL29769221 | 0.78 | AHR (1.00) | AHRCYP1B1MEN1HTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3881907-A1 | METHOD FOR DECHLORINATION OF ONE OR MORE AROMATIC ORGANOCHLORINE COMPOUND(S) CONTAINED IN AN OIL OR FORMING SAID OIL - ASSOCIATED ELECTRICAL/ELECTRONIC DEVICE AND INSTALLATION | Université de Lille (FR) | 2021-09-22 | — | — | EP | claimed |
| US-20240226160-A9 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240131072-A1 | ACTIVITY-INDUCIBLE FUSION PROTEINS HAVING A HEAT SHOCK PROTEIN 90 BINDING DOMAIN | SEATTLE CHILDREN'S HOSPITAL D/B/A SEATTLE CHILDREN'S RESEARCH INSTITUTE (US) | 2024-04-25 | — | — | US | disclosed |
| CN-117177989-A | Activity-inducible fusion proteins with heat shock protein 90 binding domain | 西雅图儿童医院以西雅图儿童研究机构名义经营 | 2023-12-05 | — | — | CN | disclosed |
| US-20230322925-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | SEATTLE CHILDREN’S HOSPITAL DBA SEATTLE CHILDREN’S RES INSTITUTE (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230172981-A1 | METHODS AND COMPOSITIONS FOR STIMULATION OF CHIMERIC ANTIGEN RECEPTOR T CELLS WITH HAPTEN LABELLED CELLS | SEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST (US) | 2023-06-08 | — | — | US | disclosed |
| US-11649288-B2 | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | SEATTLE CHILDREN'S HOSPITAL (US) | 2023-05-16 | — | — | US | disclosed |
| US-20210317407-A1 | METHODS AND COMPOSITIONS FOR STIMULATION OF CHIMERIC ANTIGEN RECEPTOR T CELLS WITH HAPTEN LABELLED CELLS | Seattle Children's Hospital (dba Seattle Children's Research Institute) | 2021-10-14 | — | — | US | disclosed |
| EP-3881907-A1 | METHOD FOR DECHLORINATION OF ONE OR MORE AROMATIC ORGANOCHLORINE COMPOUND(S) CONTAINED IN AN OIL OR FORMING SAID OIL - ASSOCIATED ELECTRICAL/ELECTRONIC DEVICE AND INSTALLATION | Université de Lille (FR) | 2021-09-22 | — | — | EP | disclosed |
| US-20200087399-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | Seattle Children's Hospital (dba Seattle Children's Research Institute) | 2020-03-19 | — | — | US | disclosed |
| WO-2018148224-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | Seattle Children's Hospital (dba Seattle Children's Research Institute) (US) | 2018-08-16 | — | — | WO | disclosed |
| US-8653119-B2 | Methods for treating transthyretin amyloid diseases | THE SCRIPPS RESEARCH INSTITUTE (US) | 2014-02-18 | — | — | US | disclosed |
| US-8168663-B2 | Pharmaceutically acceptable salt of 6-carboxy-2-(3,5 dichlorophenyl)-benzoxazole, and a pharmaceutical composition comprising the salt thereof | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-05-01 | — | — | US | disclosed |
| US-20120065237-A1 | METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES | THE SCRIPPS RESEARCH INSTITUTE (US) | 2012-03-15 | — | — | US | disclosed |
| US-20090269857-A1 | Instruments for detecting low-molecular weight substance | FUJIKURA KASEI CO., LTD. (JP) | 2009-10-29 | — | — | US | disclosed |
| US-20050148097-A1 | Instruments for detecting low-molecular weight substance | ENBIOTEC LABORATORIES C., LTD. (JP) | 2005-07-07 | — | — | US | disclosed |
| EP-1489420-A1 | INSTRUMENTS FOR DETECTING LOW-MOLECULAR WEIGHT SUBSTANCE | Enbiotec Laboratories Co., Ltd. (JP) | 2004-12-22 | — | — | EP | disclosed |
| US-5110473-A | Method and apparatus for sampling organic compounds in water | THE RESEARCH FOUNDATION OF STATE UNIVERSITY OF NEW YORK (US) | 1992-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065237-A1 | METHODS FOR TREATING TRANSTHYRETIN AMYLOID DISEASES | TTR, TTPA, PRNP | AHR 4301/4885CYP1B1 4049/4885MEN1 3669/4885 |
| US-11649288-B2 | Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents | PHOSPHO1, LCAT, CD47 | AHR 765/4885CYP1B1 4745/4885MEN1 2203/4885 |
| US-20230322925-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | PHOSPHO1, LCAT, CD47 | AHR 765/4885CYP1B1 4745/4885MEN1 2203/4885 |
| US-20200087399-A1 | PHOSPHOLIPID ETHER (PLE) CAR T CELL TUMOR TARGETING (CTCT) AGENTS | PHOSPHO1, LCAT, CD47 | AHR 765/4885CYP1B1 4745/4885MEN1 2203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.